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Background: Two-year survival rates for adult BL remain <60-65%. Furthermore, there 
is a paucity of data adding Rituximab to CODOX-M/IVAC therapy and virtually no data 
regarding the significance of serum or cerebrospinal fluid (CSF) levels. 
  
Methods: Twenty-five BL patients were enrolled. Patients had low-risk (LR) or high-risk 
(HR) disease; LR patients received 3 CODOX-M cycles, while HR had 4 alternating 
CODOX-M/IVAC cycles (Mead et al. Blood 2009). Rituximab (500mg/m2) was given x 2 
doses each cycle. Correlative analyses of paired serum and CSF Rituximab levels were 
obtained for cycles 1+3 at 24+72 hours.   
 
Results:   There were 20 HR and 5 LR patients and median age was 44 years (range, 
23-70). 3 HR and 1 LR patient were HIV+, while 15% of HR patients had CNS disease. 
Additionally, 35% of HR patients had bulk >10 cm and 40% had bone marrow 
involvement. Myelosuppression and mucositis appeared comparable with prior CODOX-
M/IVAC data.  The overall remission rate after 2 cycles was 100% with 67% complete 
remission.  At 34-month median follow-up, 2-year PFS and OS rates for all patients were 
86% and 86%, respectively (LR 2-year PFS and OS: both 100%; HR 2-year PFS and 
OS: both 82%).  Further, the 2-year PFS and OS for HR, HIV-negative patients were 
91% and 91%, respectively (disease-specific survival 100%). Two patients died from 
progressive disease (both HIV+ HR). The median serum and CSF rituximab levels for 
these patients were compared with patients without relapse (Table 1). Interestingly, 
cycle 1, 24-hour serum Rituximab levels were significantly higher among patients without 
relapse compared with the two patients who relapsed/died (P=0.042). Cycle 3, 24-hour 
Rituximab levels were of borderline significance (P=0.06).                              
  
Conclusions:  The integration of Rituximab into CODOX-M/IVAC was associated with 
excellent survival rates, especially for HIV-negative BL. Further investigation of the 
predictive value of serum Rituximab levels is warranted.  
 
 
 
 
 
Table 1. Rituximab Levels for Patients Without and With Disease Relapse. 
Chemotherapy 
cycle/hours 
after R 
infusion  
Median serum 
R level (ng/ml) 
for pts without 
relapse 
Serum R level for 2 
pts with relapse 
Median CSF R 
level (ng/ml) 
for pts without 
relapse 
CSF R levels for 2 
pts with relapse 
Pt #1 Pt #2 Pt #1 Pt #2 
     C1/24h 258,135 170,770 91,180 104 277 23 
     C1/72h 139,425 60,470 29,780 253 220 133 
     C3/24h 306,400 162,190 224,360 246 274 N/A 
     C3/72h 218,850 149,680 135,450 196 378 580 
Abbreviations: C, cycle; h, hours; pt, patient; R, Rituximab. 
 
 
